

Zoe Moodie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1773481/publications.pdf>

Version: 2024-02-01

54
papers

4,905
citations

236833

25
h-index

206029

48
g-index

58
all docs

58
docs citations

58
times ranked

6369
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2022, 225, 332-340.	1.9	1
2	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. <i>Human Immunology</i> , 2022, 83, 53-60.	1.2	3
3	Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge. <i>Cell Reports Medicine</i> , 2022, 3, 100658.	3.3	12
4	Analysis of the HIV Vaccine Trials Network 702 Phase 2bâ€“3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	1.9	11
5	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418.	6.0	468
6	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120â€“MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	13.9	144
7	Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. <i>Cell Reports Medicine</i> , 2021, 2, 100354.	3.3	316
8	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , 2021, 17, e1010016.	2.1	1
9	Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to <i>Plasmodium falciparum</i> in US Adults. <i>Clinical Infectious Diseases</i> , 2020, 71, 1481-1490.	2.9	9
10	Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial. <i>Nature Communications</i> , 2020, 11, 5578.	5.8	30
11	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. <i>PLoS ONE</i> , 2020, 15, e0234236.	1.1	9
12	Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. <i>Vaccine</i> , 2020, 38, 3531-3536.	1.7	12
13	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	3.9	27
14	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	1.6	17
15	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. <i>MSphere</i> , 2020, 5, .	1.3	3
16	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	3.9	8
17	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	1.1	16
18	Title is missing!. , 2020, 15, e0234236.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0234236.		0
20	Title is missing!. , 2020, 15, e0234236.		0
21	Title is missing!. , 2020, 15, e0234236.		0
22	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741.	2.2	25
23	Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 164-179.	0.6	9
24	Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. <i>Journal of Infectious Diseases</i> , 2018, 217, 742-753.	1.9	80
25	Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. <i>PLoS ONE</i> , 2018, 13, e0207878.	1.1	5
26	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	2.1	86
27	Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. <i>New England Journal of Medicine</i> , 2018, 379, 327-340.	13.9	557
28	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. <i>Journal of Infectious Diseases</i> , 2016, 213, 541-550.	1.9	28
29	Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. <i>PLoS ONE</i> , 2016, 11, e0147812.	1.1	42
30	Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. <i>PLoS ONE</i> , 2016, 11, e0152952.	1.1	4
31	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	1.1	23
32	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015, 10, e0137666.	1.1	30
33	Optimizing Viable Leukocyte Sampling from the Female Genital Tract for Clinical Trials: An International Multi-Site Study. <i>PLoS ONE</i> , 2014, 9, e85675.	1.1	73
34	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon- β Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study. <i>PLoS ONE</i> , 2014, 9, e108631.	1.1	23
35	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases</i> , 2014, 14, 388-396.	4.6	108
36	Vaccine Enhancement Confirmed among Men in HVTN 503-S, Final Results from a Recall Study of Phambili Participants. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A32-A33.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Incident Herpes Simplex Virus Type 2 Associated with HIV Infection in Phambili. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A29-A30.	0.5	0
38	New clinical trial designs for HIV vaccine evaluation. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 437-442.	1.5	6
39	Quantitative and Qualitative Differences in the T Cell Response to HIV in Uninfected Ugandans Exposed or Unexposed to HIV-Infected Partners. <i>Journal of Virology</i> , 2013, 87, 9053-9063.	1.5	19
40	Comparison of Sexual Behavior and HIV Risk between Two HIV-1 Serodiscordant Couple Cohorts: The CHAVI 002 Study. <i>PLoS ONE</i> , 2012, 7, e37727.	1.1	5
41	Comparing and combining data across multiple sources via integration of paired sample data to correct for measurement error. <i>Statistics in Medicine</i> , 2012, 31, 3748-3759.	0.8	11
42	Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 507-515.	4.6	330
43	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). <i>PLoS ONE</i> , 2011, 6, e21225.	1.1	131
44	Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals. <i>Journal of Virology</i> , 2011, 85, 3507-3516.	1.5	38
45	Virus-Specific CD8 ⁺ T-Cell Responses Better Define HIV Disease Progression than HLA Genotype. <i>Journal of Virology</i> , 2010, 84, 4461-4468.	1.5	50
46	Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). <i>PLoS ONE</i> , 2010, 5, e13579.	1.1	47
47	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. <i>Lancet</i> , The, 2008, 372, 1894-1905.	6.3	670
48	Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. <i>Journal of Immunological Methods</i> , 2007, 323, 39-54.	0.6	223
49	A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial. <i>Vaccine Journal</i> , 2006, 13, 1267-1277.	3.2	221
50	Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. <i>Journal of Immunological Methods</i> , 2006, 315, 121-132.	0.6	63
51	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector. <i>Journal of Infectious Diseases</i> , 2006, 194, 1638-1649.	1.9	283
52	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine. <i>Journal of Infectious Diseases</i> , 2006, 194, 1650-1660.	1.9	200
53	Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines. <i>Journal of Virology</i> , 2003, 77, 12764-12772.	1.5	90
54	Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting. <i>Journal of Virology</i> , 2003, 77, 799-803.	1.5	197